Biodesix (NASDAQ:BDSX) Director Jack Schuler Buys 82,465 Shares

Biodesix, Inc. (NASDAQ:BDSX) Director Jack Schuler bought 82,465 shares of Biodesix stock in a transaction dated Thursday, January 22nd. The stock was purchased at an average price of $10.96 per share, with a total value of $903,816.40. Following the purchase, the director directly owned 1,463,210 shares in the company, valued at approximately $16,036,781.60. This trade represents a 5.97% increase in their position. The purchase was disclosed in a legal filing with the SEC, which is available through this link.

Biodesix Stock Performance

NASDAQ BDSX traded up $0.38 on Monday, hitting $12.12. 133,451 shares of the company’s stock were exchanged, compared to its average volume of 5,179,934. The firm has a market cap of $96.44 million, a price-to-earnings ratio of -2.16 and a beta of 0.60. The firm’s 50-day moving average price is $7.63 and its two-hundred day moving average price is $7.66. Biodesix, Inc. has a fifty-two week low of $3.44 and a fifty-two week high of $21.80. The company has a debt-to-equity ratio of 41.11, a current ratio of 1.84 and a quick ratio of 1.84.

Biodesix (NASDAQ:BDSX) last posted its quarterly earnings results on Monday, November 3rd. The company reported ($1.16) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.60) by $0.44. The firm had revenue of $21.77 million for the quarter, compared to the consensus estimate of $20.98 million. Biodesix had a negative return on equity of 504.41% and a negative net margin of 49.31%. On average, research analysts expect that Biodesix, Inc. will post -0.35 EPS for the current year.

Institutional Investors Weigh In On Biodesix

Hedge funds have recently modified their holdings of the company. XTX Topco Ltd grew its holdings in shares of Biodesix by 99.4% during the second quarter. XTX Topco Ltd now owns 205,647 shares of the company’s stock worth $58,000 after buying an additional 102,494 shares in the last quarter. Millennium Management LLC purchased a new stake in Biodesix in the 3rd quarter worth approximately $113,000. Oracle Investment Management Inc. acquired a new position in Biodesix in the 3rd quarter valued at $113,000. Finally, Aberdeen Group plc purchased a new position in shares of Biodesix during the 4th quarter worth $1,784,000. 20.96% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several equities analysts recently weighed in on BDSX shares. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Biodesix in a research note on Monday, December 22nd. Wall Street Zen upgraded shares of Biodesix from a “sell” rating to a “hold” rating in a research report on Saturday, November 8th. Four research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, Biodesix presently has an average rating of “Moderate Buy” and an average price target of $32.50.

Biodesix Company Profile

Biodesix, Inc is a commercial-stage molecular diagnostics company headquartered in Boulder, Colorado, that develops and delivers blood-based tests to improve the diagnosis and management of lung diseases, including lung cancer. The company integrates advanced proteomic and, more recently, genomic technologies to offer noninvasive testing solutions designed to guide clinical decision-making. Biodesix operates a CLIA-certified and CAP-accredited laboratory, allowing it to process patient samples at scale and maintain rigorous quality standards.

The company’s flagship product, VeriStrat®, is a proteomic test that stratifies patients with non-small cell lung cancer into groups more likely to benefit from specific therapies.